Literature DB >> 26629078

Associations between the standardized uptake value of (18)F-FDG PET/CT and demographic, clinical, pathological, radiological factors in lung cancer.

Aysel Sunnetcioglu1, Ahmet Arısoy1, Yusuf Demir2, Selami Ekin2, Erkan Dogan3.   

Abstract

OBJECTIVES: (18)F-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) is extensively used to diagnose and stage of lung cancer. The aim of the current study was to investigate the correlation of demographic, clinical, pathological and radiological factors with primer tumor FDG Uptake in patients with lung cancer.
MATERIALS AND METHODS: This cross-sectional, clinical study was performed on a total of 57 lung cancer patients newly diagnosed that underwent FDG PET/CT. In addition to descriptive variables, histopathological diagnosis, tumor site and size, hemoglobin level, red cell distribution width, neutrophil to lymphocyte ratio were noted for each patient. The correlation of these variables to SUVmax values in FDG PET/CT was investigated.
RESULTS: A total of 57 patients (4 women, 53 men) with an average age of 60.8±9.4 (range: 33-89) participated in the study. Histopathological diagnoses were consistent with squamous cell carcinoma (28, 49.1%), adenocarcinoma (15, 26.3%) and small cell cancer (14, 24.6%). The SUVmax of primary tumor was positively correlated with tumor size (P<0.001). The tumor SUVmax of squamous cell carcinoma (SqCC) (17.49±8.37) was higher than that of adenocarcinoma (AC) (12.80±4.77) and small cell carcinoma (SCC) (12.40±5.80) (P=0.038).
CONCLUSION: SUVmax value was significantly higher for squamous cell carcinoma and it SUVmax values in PET scans was found to be positively correlated with tumor size. This study suggests that, tumor size and histologic subtype had influences upon FDG uptake in lung cancer.

Entities:  

Keywords:  FDG; Lung cancer; PET/CT; SUV; neutrophil-lymphocyte ratio

Year:  2015        PMID: 26629078      PMCID: PMC4658967     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  33 in total

1.  Glucose-transporter-type-I-gene amplification correlates with sialyl-Lewis-X synthesis and proliferation in lung cancer.

Authors:  J Ogawa; H Inoue; S Koide
Journal:  Int J Cancer       Date:  1997-04-22       Impact factor: 7.396

Review 2.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 3.  Nuclear factor-kappaB in cancer development and progression.

Authors:  Michael Karin
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

4.  Cancer statistics, 1999.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1999 Jan-Feb       Impact factor: 508.702

5.  Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer.

Authors:  R S Brown; J Y Leung; P V Kison; K R Zasadny; A Flint; R L Wahl
Journal:  J Nucl Med       Date:  1999-04       Impact factor: 10.057

6.  Hypoxia-Induced increase in FDG uptake in MCF7 cells.

Authors:  P Burgman; J A Odonoghue; J L Humm; C C Ling
Journal:  J Nucl Med       Date:  2001-01       Impact factor: 10.057

7.  Use of PET to monitor the response of lung cancer to radiation treatment.

Authors:  Y E Erdi; H Macapinlac; K E Rosenzweig; J L Humm; S M Larson; A K Erdi; E D Yorke
Journal:  Eur J Nucl Med       Date:  2000-07

8.  Assessment of factors influencing FDG uptake in non-small cell lung cancer on PET/CT by investigating histological differences in expression of glucose transporters 1 and 3 and tumour size.

Authors:  Naohisa Suzawa; Morihiro Ito; Shanlou Qiao; Katsunori Uchida; Motoshi Takao; Tomomi Yamada; Kan Takeda; Shuichi Murashima
Journal:  Lung Cancer       Date:  2010-09-29       Impact factor: 5.705

9.  Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings.

Authors:  M E Hebert; V J Lowe; J M Hoffman; E F Patz; M S Anscher
Journal:  Am J Clin Oncol       Date:  1996-08       Impact factor: 2.339

10.  Active and passive mechanisms of [fluorine-18] fluorodeoxyglucose uptake by proliferating and prenecrotic cancer cells in vivo: a microautoradiographic study.

Authors:  R Kubota; K Kubota; S Yamada; M Tada; T Ido; N Tamahashi
Journal:  J Nucl Med       Date:  1994-06       Impact factor: 10.057

View more
  4 in total

1.  Potential Utility of FDG PET-CT as a Non-invasive Tool for Monitoring Local Immune Responses.

Authors:  Seungho Lee; Seohee Choi; Sang Yong Kim; Mi Jin Yun; Hyoung-Il Kim
Journal:  J Gastric Cancer       Date:  2017-12-28       Impact factor: 3.720

2.  The Contribution of Fluorine 18F-FDG PET/CT to Lung Cancer Diagnosis, Staging and Treatment Planning.

Authors:  Emine Budak; Gürsel Çok; Ayşegül Akgün
Journal:  Mol Imaging Radionucl Ther       Date:  2018-06-07

3.  Investigating the Clinico-Molecular and Immunological Evolution of Lung Adenocarcinoma Using Pseudotime Analysis.

Authors:  Hyunjong Lee; Hongyoon Choi
Journal:  Front Oncol       Date:  2022-03-04       Impact factor: 6.244

4.  Relationship between SP142 PD-L1 Expression and 18F-FDG Uptake in Non-Small-Cell Lung Cancer.

Authors:  Long Zhao; Jinjun Liu; Jingyun Shi; Huoqiang Wang
Journal:  Contrast Media Mol Imaging       Date:  2020-07-20       Impact factor: 3.161

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.